Want to see JP:4893 full AI Analyst Report?

Noile-Immune Biotech Inc. (4893) Price & Analysis

0 Followers

4893 Stock Chart & Stats

¥134.00

¥9.00(4.81%)

At close: Jan 08 4:00 PM EST

¥134.00

¥9.00(4.81%)

Day’s Range― - ―

52-Week Range¥114.00 - ¥217.00

Previous CloseN/A

Volume1.93M

Average Volume (3M)85.17K

Market Cap

¥6.02B

Enterprise Value¥1.54B

Total Cash (Recent Filing)¥3.74B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)―

Beta1.41

Next Earnings

Aug 13, 2026

EPS Estimate

-5.51

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-16.31

Shares Outstanding43,276,764

10 Day Avg. Volume110,290

30 Day Avg. Volume85,173

Financial Highlights & Ratios

PEG Ratio0.41

Price to Book (P/B)1.46

Price to Sales (P/S)1151.82

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-18.33

Revenue Forecast (FY)¥300.00M

Bulls Say, Bears Say

Bulls Say

Conservative Balance Sheet (No Debt)A debt-free capital structure materially lowers solvency and interest-risk while the company spends on trials. That structural conservatism preserves optionality to fund R&D via equity or partnerships, lengthening runway and reducing near-term default risk as programs mature.

Very High Gross MarginsSustained near-100% gross margins indicate the business model can be highly scalable once products or therapies commercialize. Structural margin strength supports future profitability at scale, enabling operating leverage and attractive economics for high-value cell therapies despite current modest revenues.

Proprietary Cell‑therapy Platform And Clinical ProgramsA focused platform in engineered immune cells and active preclinical/clinical programs represent durable competitive positioning in a specialized biotech niche. Clinical-stage assets and partner collaborations can derisk programs over months and build long-term value if trial milestones and partnerships advance.

Bears Say

Sharply Declining RevenueSustained top-line contraction undermines the firm’s ability to absorb fixed R&D and clinical costs and limits internal funding capacity. Structural revenue decline over multiple years raises concerns about commercialization traction, pricing, or demand for current offerings.

Persistent Cash Burn And Negative Operating Cash FlowConsistent negative operating cash flow forces reliance on external financing or equity issuance, increasing dilution risk and governance pressure. Ongoing cash burn threatens runway and continuity of multi-year clinical programs unless offset by partnerships or new capital.

Deep Unprofitability And Negative Returns On EquityLarge net losses and materially negative ROE reflect entrenched unprofitability. Over time, persistent negative returns erode equity, constrain reinvestment capacity, and increase the need for dilutive funding, which can limit investor support and slow strategic execution.

4893 FAQ

What was Noile-Immune Biotech Inc.’s price range in the past 12 months?

Noile-Immune Biotech Inc. lowest stock price was ¥114.00 and its highest was ¥217.00 in the past 12 months.

What is Noile-Immune Biotech Inc.’s market cap?

Noile-Immune Biotech Inc.’s market cap is ¥6.02B.

When is Noile-Immune Biotech Inc.’s upcoming earnings report date?

Noile-Immune Biotech Inc.’s upcoming earnings report date is Aug 13, 2026 which is in 9 days.

How were Noile-Immune Biotech Inc.’s earnings last quarter?

Noile-Immune Biotech Inc. released its earnings results on May 14, 2026. The company reported -¥3.54 earnings per share for the quarter, beating the consensus estimate of -¥5.05 by ¥1.51.

Is Noile-Immune Biotech Inc. overvalued?

According to Wall Street analysts Noile-Immune Biotech Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Noile-Immune Biotech Inc. pay dividends?

Noile-Immune Biotech Inc. does not currently pay dividends.

What is Noile-Immune Biotech Inc.’s EPS estimate?

Noile-Immune Biotech Inc.’s EPS estimate is -5.51.

How many shares outstanding does Noile-Immune Biotech Inc. have?

Noile-Immune Biotech Inc. has 43,276,764 shares outstanding.

What happened to Noile-Immune Biotech Inc.’s price movement after its last earnings report?

Noile-Immune Biotech Inc. reported an EPS of -¥3.54 in its last earnings report, beating expectations of -¥5.05. Following the earnings report the stock price went down -3.356%.

Which hedge fund is a major shareholder of Noile-Immune Biotech Inc.?

Currently, no hedge funds are holding shares in JP:4893

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Noile-Immune Biotech Inc.

Established in 2015 and based in Minato, Japan, this company is dedicated to exploring and advancing CAR-T cell technology for use in cancer immunotherapy treatments.